Results 41 to 50 of about 47,287 (251)

ALDH2 Suppresses Ferroptosis and Promotes Bortezomib Resistance in Multiple Myeloma Through the KEAP1‐NRF2 Feedback Loop

Advanced Science, EarlyView.
ALDH2, which is overexpressed in multiple myeloma, competitively binds KEAP1 to stabilize NRF2 by blocking its ubiquitin‐proteasomal degradation. Stabilized NRF2 translocates into the nucleus to upregulate the expression of GPX4. In parallel, NRF2 binds to the ALDH2 promoter to regulate its transcription, forming a positive feedback loop that represses
Ruonan Shao, Chengcheng Liu, Xinpei Deng, Jindong Xie, Wenjian Liu, Bin Yang, Lingrui Liu, Cailu Song, Lei Li, Hua Wang, Hailin Tang   +10 more
wiley   +1 more source

Persisting Hypercalcemia and Hyperparathyroidism after Kidney Transplantation Have a Negative Impact on Graft and Patient Survival

Diagnostics
Hyperparathyroidism (HPT) with hypercalcemia, often deemed irreversible and detrimental to graft survival post-kidney transplantation (KT), prompts pre-transplant parathyroidectomy in hypercalcemic patients.
Hannes Egli, Naomi Burla, Eva Breuer, Camilla Baron, Kerstin Hübel, Olivier de Rougemont, Harald Seeger, Diana Vetter   +7 more
doaj   +1 more source

Frequency and prognostic significance of hypercalcemia in patients with multiple myeloma

Medical Journal of Babylon, 2020
Background: Multiple myeloma (MM) is defined as a clonal B-cell malignancy of the bone marrow. Hypercalcemia is associated with cancers in general and in MM specifically becomes more obvious with frequent adverse outcomes. Objectives: The objective is to
Kanar J Karim, Abid M Hassan, Hisham A Getta, Najmaddin S. H. Khoshnaw, Sana D Jalal, Akram M Mohammed, Kawa M Hasan, Dana A Abdullah, Ameer I A. Badi, Ahmed K Yassin, Banaz M Safar, Basil K Abdulla, Rawand P Shamoon, Truska A Amin, Zeki A Mohamed, Ali I Mohammed, Diveen J Hussein, Nawsherwan S Mohammed, Rezhin N Rajab, Firiad Hiwaizi   +19 more
doaj   +1 more source

Hypercalcemia Pathophysiology & Treatment. Foreword

, 2010
Hypercalcemia is a relatively common disorder, which requires specific treatment in order to control symptoms and prevent the development of organ damage.
LUMACHI, FRANCO, Basso SMM, Franco Lumachi   +2 more
core   +1 more source

Illuminating point‐of‐care diagnostics with aggregation‐induced emission biosensors

FlexMat, EarlyView.
This review highlights the application of aggregation‐induced emission luminogens (AIEgens) in point‐of‐care (POC) diagnostics for disease biomarker detection. It systematically examines a range of biosensing platforms, including lateral flow immunoassays, microfluidic chips, and electrochemiluminescence sensors, alongside their utility in detecting ...
Danni Hu, Yubing Hu, Dong Wang, Ben Zhong Tang   +3 more
wiley   +1 more source

An Unusual Case of Hypercalcemia Associated with Graves’ Disease and Vitamin D Deficiency

Clinical Medicine Insights: Endocrinology and Diabetes, 2011
Objective To present a case of hypercalcemia associated with thyrotoxicosis in a patient with vitamin D deficiency and review biochemical changes during the course of treatment. Methods We report a case, describe the changes in serum calcium, phosphorus,
Evgenia Korytnaya, Nagashree Gundu Rao, Jane V. Mayrin   +2 more
doaj   +1 more source

Causes of hypercalcemia in renal transplant recipients: persistent hyperparathyroidism and others [PDF]

Brazilian Journal of Medical and Biological Research
Hypercalcemia is common in patients after kidney transplantation (KTx) and is associated with persistent hyperparathyroidism in the majority of cases. This retrospective, single-center study evaluated the prevalence of hypercalcemia after KTx.
M. Moyses-Neto, T.M.P. Garcia, M.E.P. Nardin, V.A. Muglia, C.A.F. Molina, E.A. Romao   +5 more
doaj   +2 more sources

Cinacalcet for the Treatment of Humoral Hypercalcemia of Malignancy: An Introductory Case Report with a Pathophysiologic and Therapeutic Review

Case Reports in Oncology, 2020
Hypercalcemia is an ominous development in the course of malignancy associated with a mean survival of only several months. A majority of cases of hypercalcemia are related to humoral hypercalcemia of malignancy (HHM), where hypercalcemia is caused by ...
Michael Sheehan, Sabo Tanimu, Yusuf Tanimu, Jessica Engel, Adedayo Onitilo   +4 more
doaj   +1 more source

Management of hypercalcemia of malignancy [PDF]

, 2016
Malignancy is one of the most common causes of hypercalcemia, particularly in cancer associated with bone metastases. Hypercalcemia occurs in up to 20% to 30% of cancer patients at some time during the course of their disease.
Thomas, Sonia, Chung, Soo-Hwan
core  

Malignancy-Induced Hypercalcemia—Diagnostic Challenges

, 2017
Hypercalcemia in children is a rare metabolic finding. The clinical picture is usually non-specific, and the etiology includes several entities (metabolic, nutritional, drug-induced, inflammatory, cancer-associated, or genetic) depending on the age at ...
Claire Hoyoux, Corina Ramona Nicolescu, Jacques Lombet   +2 more
core   +1 more source